Sekisui XenoTech Hiring and Growing to Meet Customer Demand
News Jan 04, 2018
For over 20 years, Sekisui XenoTech has been known for its dedication to sound science, expert guidance and support in helping customers obtain data that meets or exceeds regulatory agency expectations when developing new therapeutics.
The company hired a record number of new staff over the past year in order to meet current demand for its products and services, which are utilized to optimize the discovery, development, and approval of new drugs and other compounds. Several previous Sekisui XenoTech employees also returned to the company. The new staff span Sekisui XenoTech’s contract research, quality assurance, business, IT, and other departments.
“Our hiring efforts are a reflection of our commitment to maintaining strict quality standards while meeting client needs and timelines,” explained Toshinari Ohara, PhD, CEO of Sekisui XenoTech. He added, “2017 ties 2011 for our second-highest number of new hires in a single year.”
One of the new additions was industry veteran Darren Warren, PhD, who became the company’s new COO in October. Upon joining Sekisui XenoTech, Dr. Warren noted, “I am excited to become a member of an organization with the distinguished performance history, leadership team strength, depth of scientific expertise, and position of market leadership that Sekisui XenoTech enjoys, and that holds an optimistic outlook towards future growth while maintaining commitment to excellence in providing a positive customer experience as well as outstanding contract services and products.”
In addition to growth, the company has made other internal changes. Dr. Ohara commented, “While hiring talent from outside the organization has many positive effects, such as introducing new ideas and expertise, we have also been focused on ongoing training and career advancement for our existent staff.” Sekisui XenoTech awarded numerous promotions to its staff this year, which prominently included elevating Joanna Barbara, PhD, to the position of Vice President of Scientific Operations and Brian Ogilvie, PhD, to the position of Vice President of Scientific Consulting. Joanna and Brian share a combined 30 years of experience with the company.
A new chemical synthesis strategy to harvest the rich information found in natural products has led to the identification of novel, simpler derivatives with potential to selectively protect neurons, important for neurodegenerative diseases like Alzheimer’s disease, or to prevent the body’s immune system from rejecting organ transplants, according to a Baylor University-led study.READ MORE